Trial Profile
Glimepiride monotherapy vs. combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary) ; Glimepiride
- Indications Diabetes mellitus
- Focus Therapeutic Use
- Acronyms GLIMLINA
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 13 Jul 2020 Results published in the Diabetes Care Journal.
- 16 Jun 2020 Primary endpoint (Mean amplitude of glycaemic excursions (MAGE)) has not been met, according to results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.